Get the Stockscreener App
11.68
1.35%
-0.16
Alvotech stock is traded at $11.68, with a volume of 62,728.
It is down -1.35% in the last 24 hours and down -10.70% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
See More
Previous Close:
$11.84
Open:
$11.88
24h Volume:
62,728
Relative Volume:
0.67
Market Cap:
$3.54B
Revenue:
$306.77M
Net Income/Loss:
$-618.38M
P/E Ratio:
-5.9289
EPS:
-1.97
Net Cash Flow:
$-343.00M
1W Performance:
-5.96%
1M Performance:
-10.70%
6M Performance:
-17.69%
1Y Performance:
+18.58%
1-Day Range:
$11.61
$11.88
1-Week Range:
$11.61
$12.44
52-Week Range:
$9.08
$18.00
Alvotech Stock (ALVO) Company Profile
Compare ALVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
11.68 | 3.54B | 306.77M | -618.38M | -343.00M | -1.97 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech’s Eylea Biosimilar ‘Keeps In Mind’ US Patent Landscape - Citeline
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth hurdles - Investing.com
Alvotech (ALVO) Shares Gap Down to $11.94 on Nov 22 - GuruFocus.com
Alvotech’s Position In The Coming Biosimilar Gold Rush (NASDAQ:ALVO) - Seeking Alpha
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates - MSN
Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023) - Yahoo Finance
Earnings call: Alvotech reported revenues of $128 million - Investing.com India
Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements - Investing.com Canada
Alvotech Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call: Alvotech reported revenues of $128 million By Investing.com - Investing.com Canada
Alvotech earnings missed, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Alvotech earnings missed, revenue fell short of estimates - Investing.com India
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges By Investing.com - Investing.com Australia
Alvotech : First 9 Months Earnings and Business Update 2024 - Marketscreener.com
Alvotech Showcases Strong Financial Growth and Expansion - TipRanks
Alvotech Reports Financial Results for the First Nine Months of 2024 - The Manila Times
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges - Investing.com
EMA Accepts Marketing Authorization Application for Alvotech’s AVT05 (golimumab) - JD Supra
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - The Manila Times
Alvotech Attending Citi's Global Healthcare Conference on - GlobeNewswire
Alvotech to Present at Citi and Evercore Healthcare Conferences in December | ALVO Stock News - StockTitan
ADVANZ PHARMAEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi - Marketscreener.com
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi - BioPharma-Reporter.com
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for its biosimilar of J&J’s Simponi - BioPharma-Reporter.com
EMA accepts Alvotech and Advanz Pharma’s AVT05 MAA - Pharmaceutical Technology
Alvotech application for Simponi biosimilar accepted by EMA - MSN
Alvotech’s AVT05 Biosimilar Application Accepted by EMA - TipRanks
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - The Manila Times
European Medicines Agency Confirms Acceptance of Marketing - GlobeNewswire
Alvotech and Teva Announce FDA Approval of Additional Presentation for Ustekinumab Biosimilar - JD Supra
Alvotech Petitions FDA To Deny Interchangeability For Rival Stelara Biosimilars - Citeline News & Insights
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - The Manila Times
Alvotech to Report Financial Results for the First Nine - GlobeNewswire
Alvotech, Teva obtain FDA nod for new Selarsdi indication - Drug Store News
Exploring High Growth Tech Stocks In The US October 2024 - Simply Wall St
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - StockTitan
Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire
FDA approves Alvotech and Teva’s SELARSDI for new indications - MSN
Alvotech's SWOT analysis: biosimilar powerhouse stock faces growth hurdles - Investing.com
Teva, Alvotech get expanded FDA approval for Stelara biosimilar - MSN
Teva, Alvotech get expanded FDA approval for Stelara biosimilar (NYSE:TEVA) - Seeking Alpha
Alvotech and Teva Secure FDA Approval for SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - The Manila Times
Teva, Alvotech announce U.S. FDA approval of presentation of SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional - GlobeNewswire
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):